Cost Effectiveness of Fesoterodine and Tolterodine for the Treatment of Overactive Bladder with Urge Urinary Incontinence in Spain and Finland

被引:0
作者
Javier C. Angulo
Antti Valpas
Javier Rejas
Kari Linden
Marion Kvasz
Sonya J. Snedecor
机构
[1] Hospital Universitario de Getafe,Servicio de Urología
[2] South Karelia Social and Health Care District,undefined
[3] Pfizer,undefined
[4] S.L.U,undefined
[5] Pfizer Oy,undefined
[6] Pfizer International,undefined
[7] Pharmerit International,undefined
来源
Clinical Drug Investigation | 2014年 / 34卷
关键词
Overactive Bladder; Oxybutynin; Tolterodine; Clinical Trial Data; Probabilistic Sensitivity Analysis;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:297 / 307
页数:10
相关论文
共 163 条
[1]  
Milsom I(2001)How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study BJU Int 87 760-766
[2]  
Abrams P(2005)Prevalence of overactive bladder in Spain: a population-based study Arch Esp Urol 58 131-138
[3]  
Cardozo L(2007)Is the prevalence of overactive bladder overestimated? A population-based study in Finland PLoS One 2 e195-1314
[4]  
Roberts RG(2006)Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study Eur Urol 50 1306-519
[5]  
Thuroff J(2005)Costs associated with the management of overactive bladder and related comorbidities Pharmacotherapy 25 511-1057
[6]  
Wein AJ(2006)The current and future burden and cost of overactive bladder in five European countries Eur Urol 50 1050-394
[7]  
Castro D(2000)A survey of physician attitudes and practices concerning cost-effectiveness in patient care West J Med 173 390-877
[8]  
Espuna M(2012)Influence of cost-effectiveness information on prescribing practices Finn Med J 67 873-180
[9]  
Prieto M(2011)High-value, cost-conscious health care: concepts for clinicians to evaluate the benefits, harms, and costs of medical interventions Ann Intern Med 154 174-61
[10]  
Badia X(2008)Information on cost-effectiveness: an essential product of a national comparative effectiveness program Ann Intern Med 148 956-246